

Cardiac Amyloidosis: Practice Essentials for Diagnosis and Management

Selected Bibliography

Adams D, Gonzalez-Duarte A, William D. O’Riordan WD, et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. *N Engl J Med*. 2018;379:11-21.

Alexander KM, Orav J, Singh A, et al. Geographic disparities in reported US amyloidosis mortality from 1979 to 2015: Potential under detection of cardiac amyloidosis. *JAMA Cardiol*. 2018;3:865-870.

Alexander KM, Singh A, Falk RH. Novel pharmacotherapies for cardiac amyloidosis. *Pharmacol Ther*. 2017;180:129-138.

American Society of Nuclear Cardiology. Cardiac Amyloidosis Practice Points. 99mTechnetium-pyrophosphate imaging for transthyretin cardiac amyloidosis. Available at: [www.asnc.org/files/19110%20ASNC%20Amyloid%20Practice%20Points%20WEB\(2\).pdf](http://www.asnc.org/files/19110%20ASNC%20Amyloid%20Practice%20Points%20WEB(2).pdf).

Benson MD, Waddington-Cruz M, Berk JL, et al. Inotersen treatment for patients with hereditary transthyretin amyloidosis. *N Engl J Med*. 2018;379:22-31.

Bokhari S, Castaño A, Pozniakoff T, Deslisle S, Latif F, Maurer MS. (99m)Tc-pyrophosphate scintigraphy for differentiating light-chain cardiac amyloidosis from the transthyretin-related familial and senile cardiac amyloidosis. *Circ Cardiovasc Imaging*. 2013;6:195-201.

Bokhari S, Morgenstern R, Weinberg R, Kinkhabwala M, Panagiotou D, Castano A, DeLuca A, Kontak A, Jin Z, Maurer MS. Standardization of 99mTechnetium pyrophosphate imaging methodology to diagnose TTR cardiac amyloidosis. *J Nucl Cardiol*. 2018;25:181–190.

Bravo PE, Dorbala S. Targeted nuclear imaging probes for cardiac amyloidosis. *Curr Cardiol Rep*. 2017;19:59.

Castano A, Haq M, Narotsky DL, et al. Multicenter study of planar technetium 99m pyrophosphate cardiac imaging. Predicting survival for patients with ATTR cardiac amyloidosis. *JAMA Cardiol*. 2016;1:880-889.

Cavalcante JL, Rijal S, Abdelkarim I. Cardiac amyloidosis is prevalent in older patients with aortic stenosis and carries worse prognosis. *J Cardiovasc Magn Reson*. 2017;19:98.

Connors LH, Sam F, Skinner M, et al. Heart failure resulting from age-related cardiac amyloid disease associated with wild-type transthyretin: A prospective, observational cohort study. *Circulation*. 2016;133:282-290.



Donnelly JP, Hanna M. Cardiac amyloidosis: An update on diagnosis and treatment. *Cleve Clin J Med*. 2017;84(12 Suppl 3):12-26.

Dorbala S, Falk R. Imaging cardiac amyloidosis: Patient page. *J Nucl Cardiol*. 2019;26:217-221.

Falk RH. Cardiac amyloidosis: A treatable disease, often overlooked. *Circulation*. 2011;124:1079–1085.

Gillmore JD, Maurer MS, Falk RH, Merlini G, Damy T, Dispenzieri A, Wechalekar AD, et al. Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. *Circulation*. 2016;133(24):2404-2412.

Maurer MS, Elliott P, Comenzo R, Semigran M, Rapezzi C. Addressing common questions encountered in the diagnosis and management of cardiac amyloidosis. *Circulation*. 2017;135:1357-1377.

Maurer MS, Schwartz JH, Gundapaneni B, Elliott PM, Merlini G, Waddington-Cruz M, et al. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. *N Eng J Med*. 2018; 379:1007-1016.

Mints YY, Doros G, Berk JL, Connors LH, Ruberg FL. Features of atrial fibrillation in wild-type transthyretin cardiac amyloidosis: a systematic review and clinical experience. *ESC Heart Fail*. 2018;5:772-779.

Ruberg FL, Berk JL. Transthyretin (TTR) cardiac amyloidosis. *Circulation*. 2012a;126:1286-1300.

Ruberg FL, Maurer MS, Judge DP, Zeldenrust S, Skinner M, Kim AY, et al. Prospective evaluation of the morbidity and mortality of wild-type and V122I mutant transthyretin amyloid cardiomyopathy: The Transthyretin Amyloidosis Cardiac Study (TRACS). *Am Heart J*. 2012b;164:222-228.

Siddiqi OK, Ruberg FL. Cardiac amyloidosis: An update on pathophysiology, diagnosis, and treatment. *Trends Cardiovasc Med*. 2018;28:10-21.

Siddiqi OK, Ruberg FL. Challenging the myths of cardiac amyloidosis. *Eur Heart J*. 2017;38:1909-1912.

Singh V, Falk R, Di Carli MF, Kijewski M, Rapezzi C, Dorbala S. State-of-the-art radionuclide imaging in cardiac transthyretin amyloidosis. *J Nucl Cardiol*. 2019;26:158-173.

Soman P, Masri A. Setting the stage for the next step in cardiac amyloidosis imaging: Serial quantitative studies to assess disease activity. *J Nucl Cardiol*. 2018;25:1571-1573.



Vranian MN, Sperry BW, Valent J, Hanna M. Emerging advances in the management of cardiac amyloidosis. *Curr Cardiol Rep.* 2015;17:100.

White JA and Fine NM. Recent advances in cardiovascular imaging relevant to the management of patients with suspected cardiac amyloidosis. *Curr Cardiol Rep.* 2016;18:77.

